Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB 7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• GRB7 protein over-expression and clinical outcome in breast cancer

  2011cited by this paper
• Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.

  2010cited by this paper
• Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer

  2010cited by this paper
• Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.

  2009cited by this paper
• Weighted analyses for cohort sampling designs

  2009cited by this paper
• BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

  2009cited by this paper
• Thiazole Antibiotics Target FoxM1 and Induce Apoptosis in Human Cancer Cells

  2009cited by this paper
• Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

  2009cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009influential reference
• The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting

  2008cited by this paper
• AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

  2008cited by this paper
• Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

  2008cited by this paper
• Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.

  2008cited by this paper
• Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

  2008cited by this paper
• Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.

  2008cited by this paper
• The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor‐negative, invasive breast cancer: The California Cancer Registry, 1999–2004

  2008cited by this paper
• Targeted therapy for cancer using PARP inhibitors.

  2008cited by this paper
• In Vitro and In Vivo Analysis of B-Myb in Basal-Like Breast Cancer

  2008cited by this paper
• Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

  2008cited by this paper
• Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

  2007cited by this paper
• Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

  2007cited by this paper
• The Genomic Landscapes of Human Breast and Colorectal Cancers

  2007cited by this paper
• An investigation of two multivariate permutation methods for controlling the false discovery proportion

  2007cited by this paper
• AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

  2007cited by this paper
• Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting.

  2007cited by this paper
• NMR analysis of G7-18NATE, a nonphosphorylated cyclic peptide inhibitor of the Grb7 adapter protein.

  2007cited by this paper
• Concordance of local and central laboratory hormone and HER2 receptor status in ECOG 2197

  2007cited by this paper
• Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis.

  2006cited by this paper
• Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

  2006cited by this paper
• Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

  2005cited by this paper
• Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

  2005cited by this paper
• Controlling the number of false discoveries: application to high-dimensional genomic data

  2004cited by this paper
• Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay.

  2004cited by this paper
• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

  2004cited by this paper
• Grb7 in intracellular signaling and its role in cell regulation.

  2004cited by this paper
• VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

  2004cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Alpha v integrin inhibitors and cancer therapy.

  2003cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• The Grb7 family proteins: structure, interactions with other signaling molecules and potential cellular functions

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• C. elegans cell migration gene mig-10 shares similarities with a family of SH2 domain proteins and acts cell nonautonomously in excretory canal development.

  1997cited by this paper

• No citing papers are available for this paper.